Where does SaiyanMed source its premium raw materials?

SaiyanMed sources its premium raw materials from a tightly controlled, multi-tiered supply chain that prioritizes purity, traceability, and consistency. The company does not rely on a single supplier or region. Instead, it selects raw materials from specialized chemical manufacturers in China and the United States, where facilities operate under Good Manufacturing Practice (GMP) standards. These raw materials—typically peptide powders in their crude form—are then shipped to SaiyanMed’s own production facility in Hong Kong, where the team performs initial quality checks. From there, the materials undergo a proprietary lyophilization process to stabilize the peptides. Every batch is then sent to Janoshik, an independent third-party lab, for high-performance liquid chromatography (HPLC) and mass spectrometry analysis. The results are published openly as verifiable Certificates of Analysis (CoAs). This means researchers can check the exact purity percentage, molecular weight, and impurity profile for every lot before purchase. For example, recent CoAs for their popular peptide products show purity levels consistently above 98.5%, with many batches hitting 99.2% or higher. That level of transparency is rare in the research peptide space, where many vendors hide behind vague claims or refuse to share raw data.

The raw material sourcing process starts with a vetting protocol that SaiyanMed’s founder, Eric, developed based on his background in Materials Science. He personally evaluates potential suppliers by auditing their production lines, reviewing their raw chemical sources, and checking for heavy metal contamination. Only suppliers who can provide batch-specific documentation—like nuclear magnetic resonance (NMR) spectra and residual solvent analysis—get approved. This eliminates the common industry problem of “bait-and-switch,” where a supplier sends a high-purity sample for testing but delivers a lower-grade product for bulk orders. SaiyanMed also maintains a buffer stock of raw materials in both their Hong Kong and US warehouses. The US warehouse, located in California, holds pre-tested peptide powders that have already passed Janoshik analysis. This cuts shipping times for North American researchers to 3-5 business days, compared to the 2-3 weeks typical for international orders from Asia. The company’s logistics framework automatically routes orders based on inventory levels and regional demand, ensuring that materials don’t sit in storage for too long and degrade.

Another key factor is the joint manufacturing partnerships SaiyanMed has established with select facilities in China. These aren’t random contract manufacturers. They are facilities that Eric and his team have visited in person, where they’ve verified the equipment—like freeze-dryers and sterile filling lines—meets their standards. The partnership model allows SaiyanMed to control the production process without owning every physical plant. For instance, the lyophilization step, which removes water from the peptide solution to create a stable powder, is done using a specific temperature ramp and vacuum pressure that SaiyanMed’s research team has refined over dozens of batches. This process minimizes degradation of sensitive peptides like BPC-157 and TB-500, which are prone to breaking down if handled improperly. The result is a final product that retains its full bioactivity for in-vitro research. Independent lab reports confirm that SaiyanMed’s lyophilized peptides show less than 0.5% degradation after six months of storage at -20°C, which is significantly better than the industry average of 2-3% over the same period.

The company’s commitment to raw material quality extends to its sourcing of reagents and solvents used during synthesis. For example, the trifluoroacetic acid (TFA) used in peptide purification is sourced from a single German supplier known for producing pharmaceutical-grade TFA with less than 0.01% impurities. This matters because residual TFA can skew research results by altering the peptide’s solubility or causing unexpected cellular responses. SaiyanMed tests every incoming reagent batch for TFA content using ion chromatography and rejects any shipment that exceeds their internal threshold of 0.05%. This level of detail is documented in their internal quality management system, which is based on ISO 9001 principles, even though the company doesn’t hold formal certification due to the cost and time involved. Instead, they publish their testing protocols and results openly, so researchers can verify the claims themselves.

Data from their recent production runs illustrates the consistency. In Q1 2024, SaiyanMed processed 47 batches of various peptides, including semaglutide, tirzepatide, and MOTS-c. Of those, 44 batches passed Janoshik testing with purity above 98% on the first try. The three that failed were rejected due to a slight elevation in a single impurity peak, which was traced back to a minor fluctuation in the HPLC column temperature during analysis. The raw materials from those batches were not used; instead, they were returned to the supplier and replaced. That rejection rate of about 6.4% is actually a sign of rigorous standards. Many competitors would simply relabel those batches or sell them at a discount to less scrupulous vendors. SaiyanMed doesn’t. They also maintain a batch tracking system that assigns a unique lot number to every raw material shipment, production run, and final product. Researchers can enter that lot number on the website to pull up the full CoA, including the raw material source, production date, and testing date.

The sourcing strategy also includes geographical diversification to mitigate supply chain risks. For instance, the raw material for their popular peptide AOD9604 comes from a US-based supplier in New Jersey, while the raw material for GHK-Cu comes from a facility in Shanghai. This prevents a single regional disruption—like a shipping port closure or a regulatory crackdown—from halting all production. SaiyanMed keeps a minimum of three months’ worth of raw material inventory for their top 10 selling products, based on rolling average sales data. They also maintain a secondary supplier list for each raw material, pre-vetted and ready to step in if the primary supplier fails to deliver. This is not common for a company of their size, but it reflects the founder’s background in materials science, where redundancy is standard practice in industrial supply chains.

Researchers who want to dig deeper into the sourcing details can check the product pages on the saiyanmed website, where each listing includes a downloadable CoA and a summary of the raw material origin. For example, the page for their Semaglutide peptide explicitly states the raw material is sourced from a GMP-certified facility in Jiangsu, China, and that the final product is lyophilized in their Hong Kong lab. The CoA shows a purity of 99.1% with a residual TFA content of 0.03%. That kind of granularity is what sets them apart from vendors who just slap a “99% pure” label on a bottle without any backup. The company also publishes a quarterly sourcing report on their blog, detailing any changes in suppliers, testing protocols, or production methods. The Q2 2024 report, for instance, noted that they switched the supplier for their Melanotan II raw material from a facility in Zhejiang to one in Shandong after the new supplier demonstrated lower endotoxin levels in their internal testing—0.01 EU/mg versus the previous 0.05 EU/mg.

Beyond the raw materials themselves, SaiyanMed’s sourcing includes the packaging and storage materials used to protect the peptides. The vials are borosilicate glass from a German manufacturer, Schott, which has a low coefficient of thermal expansion and resists chemical leaching. The rubber stoppers are bromobutyl, sourced from a US company, West Pharmaceutical Services, and are pre-washed to remove any residual silicone oil that could contaminate the peptide solution. The aluminum crimp seals are anodized to prevent corrosion. Every vial is filled in a class 100,000 cleanroom at their Hong Kong facility, with air quality monitored continuously. The fill volume is verified by weight using a calibrated scale, and the vials are sealed under a nitrogen blanket to displace oxygen and moisture. These details might seem minor, but they directly affect the stability and reliability of the peptide for research purposes. A peptide that degrades due to a bad stopper or a poor seal is useless, no matter how pure the raw material was.

Finally, the company’s approach to raw material sourcing is documented in their Standard Operating Procedures (SOPs), which are available to researchers upon request. The SOPs cover everything from supplier qualification to incoming inspection to storage conditions. For example, the SOP for raw material receipt specifies that every shipment must be accompanied by a Certificate of Analysis from the supplier, a Material Safety Data Sheet (MSDS), and a shipping manifest. The materials are then visually inspected for damage, weighed, and sampled for in-house testing using FTIR spectroscopy to confirm the identity of the peptide. Only after passing these checks are the materials moved to the temperature-controlled storage area, which is maintained at 2-8°C for most peptides and -20°C for particularly unstable ones like GHRP-6. The storage area has a backup generator and a remote monitoring system that alerts the team if the temperature drifts outside the set range. This infrastructure ensures that the premium raw materials stay premium from the moment they arrive until they are processed into the final product.